 Michael Strong
Concepts (411)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 27 | 2025 | 367 | 5.900 |
Why?
| | Genome, Bacterial | 15 | 2024 | 152 | 3.850 |
Why?
| | Mycobacterium | 11 | 2023 | 112 | 3.570 |
Why?
| | Nontuberculous Mycobacteria | 16 | 2024 | 209 | 3.190 |
Why?
| | Mycobacterium tuberculosis | 19 | 2023 | 327 | 2.680 |
Why?
| | Mycobacterium abscessus | 12 | 2025 | 119 | 2.400 |
Why?
| | Whole Genome Sequencing | 5 | 2025 | 175 | 1.670 |
Why?
| | Mycobacterium Infections | 6 | 2021 | 62 | 1.560 |
Why?
| | Amyotrophic Lateral Sclerosis | 3 | 2021 | 101 | 1.530 |
Why?
| | Neurodegenerative Diseases | 8 | 2025 | 142 | 1.490 |
Why?
| | Cystic Fibrosis | 13 | 2025 | 1132 | 1.330 |
Why?
| | Tuberculosis | 8 | 2023 | 286 | 1.270 |
Why?
| | Frontotemporal Dementia | 4 | 2023 | 57 | 1.150 |
Why?
| | Genomics | 7 | 2021 | 820 | 1.140 |
Why?
| | Phylogeny | 14 | 2021 | 1003 | 1.030 |
Why?
| | Genotype | 6 | 2024 | 1866 | 0.960 |
Why?
| | Antitubercular Agents | 8 | 2023 | 209 | 0.930 |
Why?
| | Bacteriophages | 3 | 2022 | 108 | 0.860 |
Why?
| | Genome, Viral | 3 | 2021 | 224 | 0.860 |
Why?
| | Lung Diseases | 3 | 2022 | 786 | 0.840 |
Why?
| | Computational Biology | 9 | 2018 | 673 | 0.840 |
Why?
| | Methylobacterium | 1 | 2023 | 3 | 0.820 |
Why?
| | Sequence Analysis, DNA | 8 | 2022 | 820 | 0.790 |
Why?
| | High-Throughput Nucleotide Sequencing | 6 | 2022 | 546 | 0.780 |
Why?
| | Protein Domains | 1 | 2024 | 306 | 0.760 |
Why?
| | Herpesvirus 4, Human | 5 | 2016 | 168 | 0.760 |
Why?
| | Genetic Variation | 8 | 2021 | 999 | 0.730 |
Why?
| | Drug Resistance, Bacterial | 8 | 2024 | 193 | 0.730 |
Why?
| | Multifunctional Enzymes | 1 | 2021 | 2 | 0.690 |
Why?
| | Viral Nonstructural Proteins | 1 | 2021 | 67 | 0.690 |
Why?
| | Lipodystrophy | 1 | 2021 | 14 | 0.690 |
Why?
| | RNA-Binding Protein FUS | 1 | 2021 | 15 | 0.680 |
Why?
| | RNA Helicases | 1 | 2021 | 32 | 0.670 |
Why?
| | Lamin Type A | 1 | 2021 | 48 | 0.670 |
Why?
| | Lysogeny | 1 | 2020 | 5 | 0.670 |
Why?
| | Databases, Genetic | 3 | 2018 | 246 | 0.670 |
Why?
| | Prophages | 1 | 2020 | 8 | 0.660 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 125 | 0.660 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 636 | 0.650 |
Why?
| | DNA-Binding Proteins | 5 | 2024 | 1500 | 0.630 |
Why?
| | Plasmids | 1 | 2020 | 369 | 0.620 |
Why?
| | Mutation, Missense | 2 | 2021 | 341 | 0.610 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1977 | 0.610 |
Why?
| | Bacterial Proteins | 10 | 2016 | 935 | 0.610 |
Why?
| | DNA Helicases | 1 | 2021 | 144 | 0.610 |
Why?
| | Viruses | 1 | 2021 | 163 | 0.590 |
Why?
| | Cross Infection | 4 | 2025 | 260 | 0.580 |
Why?
| | Hawaii | 5 | 2023 | 41 | 0.580 |
Why?
| | Humans | 79 | 2025 | 142526 | 0.580 |
Why?
| | Mutation | 3 | 2021 | 4024 | 0.560 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2146 | 0.550 |
Why?
| | Soil Microbiology | 2 | 2020 | 215 | 0.550 |
Why?
| | Equipment Contamination | 2 | 2016 | 71 | 0.550 |
Why?
| | DNA, Bacterial | 5 | 2021 | 333 | 0.550 |
Why?
| | Microbial Sensitivity Tests | 5 | 2024 | 373 | 0.540 |
Why?
| | Tissue Adhesives | 1 | 2017 | 23 | 0.520 |
Why?
| | Dura Mater | 1 | 2017 | 34 | 0.510 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2017 | 65 | 0.490 |
Why?
| | Respiratory System | 1 | 2017 | 156 | 0.480 |
Why?
| | Research Personnel | 1 | 2018 | 177 | 0.480 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2021 | 345 | 0.470 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2016 | 78 | 0.470 |
Why?
| | Cardiac Surgical Procedures | 2 | 2019 | 588 | 0.460 |
Why?
| | Viral Matrix Proteins | 1 | 2015 | 30 | 0.460 |
Why?
| | Frontotemporal Lobar Degeneration | 1 | 2015 | 19 | 0.460 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 325 | 0.460 |
Why?
| | Software | 5 | 2022 | 682 | 0.450 |
Why?
| | Databases, Nucleic Acid | 1 | 2014 | 39 | 0.440 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2015 | 117 | 0.440 |
Why?
| | Disease Outbreaks | 4 | 2025 | 428 | 0.430 |
Why?
| | Cerebrovascular Disorders | 2 | 2025 | 100 | 0.420 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2015 | 100 | 0.420 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 207 | 0.410 |
Why?
| | Stomach Neoplasms | 1 | 2015 | 118 | 0.410 |
Why?
| | Skin Diseases, Bacterial | 1 | 2013 | 21 | 0.410 |
Why?
| | Systems Biology | 1 | 2014 | 73 | 0.400 |
Why?
| | Microbiota | 1 | 2021 | 756 | 0.400 |
Why?
| | Genetic Predisposition to Disease | 3 | 2019 | 2388 | 0.390 |
Why?
| | Tuberculosis, Pulmonary | 4 | 2016 | 129 | 0.390 |
Why?
| | Education, Medical, Graduate | 1 | 2018 | 539 | 0.390 |
Why?
| | tau Proteins | 5 | 2025 | 98 | 0.380 |
Why?
| | Respiratory Tract Diseases | 1 | 2014 | 180 | 0.370 |
Why?
| | Ontario | 6 | 2025 | 96 | 0.350 |
Why?
| | Cognition Disorders | 1 | 2015 | 521 | 0.350 |
Why?
| | Molybdenum | 2 | 2021 | 10 | 0.340 |
Why?
| | Cognitive Dysfunction | 4 | 2025 | 429 | 0.340 |
Why?
| | Amino Acid Substitution | 2 | 2021 | 309 | 0.320 |
Why?
| | Sputum | 6 | 2021 | 311 | 0.320 |
Why?
| | Metagenomics | 2 | 2021 | 180 | 0.310 |
Why?
| | Hydrogels | 1 | 2017 | 690 | 0.310 |
Why?
| | Protein Binding | 4 | 2024 | 2249 | 0.300 |
Why?
| | Alzheimer Disease | 3 | 2023 | 603 | 0.300 |
Why?
| | Physicians | 1 | 2018 | 937 | 0.290 |
Why?
| | Proteins | 3 | 2014 | 1013 | 0.290 |
Why?
| | Lung | 6 | 2023 | 4078 | 0.280 |
Why?
| | RNA, Viral | 2 | 2024 | 702 | 0.280 |
Why?
| | RNA | 2 | 2014 | 929 | 0.280 |
Why?
| | United States | 10 | 2022 | 15447 | 0.270 |
Why?
| | Proteomics | 4 | 2010 | 1152 | 0.270 |
Why?
| | Genes, Bacterial | 4 | 2017 | 165 | 0.260 |
Why?
| | Treatment Outcome | 4 | 2025 | 11298 | 0.250 |
Why?
| | Gene Expression Profiling | 9 | 2023 | 1773 | 0.250 |
Why?
| | Chromosome Mapping | 2 | 2023 | 502 | 0.240 |
Why?
| | Canada | 2 | 2018 | 428 | 0.240 |
Why?
| | Bacterial Typing Techniques | 2 | 2017 | 44 | 0.240 |
Why?
| | Cluster Analysis | 4 | 2014 | 522 | 0.220 |
Why?
| | Tuberculosis, Multidrug-Resistant | 3 | 2016 | 50 | 0.220 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 398 | 0.220 |
Why?
| | Evolution, Molecular | 2 | 2021 | 504 | 0.210 |
Why?
| | Soil | 3 | 2022 | 209 | 0.210 |
Why?
| | Virulence | 3 | 2020 | 271 | 0.210 |
Why?
| | DNA Repeat Expansion | 2 | 2014 | 12 | 0.210 |
Why?
| | Reference Standards | 1 | 2024 | 181 | 0.210 |
Why?
| | Microvessels | 1 | 2025 | 89 | 0.210 |
Why?
| | Gene Expression | 2 | 2021 | 1496 | 0.200 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2024 | 103 | 0.200 |
Why?
| | Immunity, Innate | 3 | 2021 | 856 | 0.200 |
Why?
| | Self Concept | 1 | 2025 | 255 | 0.200 |
Why?
| | Brain | 3 | 2025 | 2875 | 0.200 |
Why?
| | White Matter | 1 | 2025 | 146 | 0.200 |
Why?
| | Multigene Family | 1 | 2003 | 204 | 0.200 |
Why?
| | Data Accuracy | 1 | 2023 | 63 | 0.200 |
Why?
| | Neuropsychological Tests | 3 | 2017 | 1096 | 0.200 |
Why?
| | Scoliosis | 1 | 2025 | 222 | 0.190 |
Why?
| | Transcriptome | 4 | 2023 | 1015 | 0.190 |
Why?
| | Gene Expression Regulation, Bacterial | 5 | 2023 | 325 | 0.190 |
Why?
| | Spinal Fusion | 1 | 2025 | 260 | 0.180 |
Why?
| | Virus Replication | 2 | 2016 | 542 | 0.180 |
Why?
| | Phosphoproteins | 1 | 2024 | 334 | 0.180 |
Why?
| | Protein Conformation, beta-Strand | 1 | 2021 | 18 | 0.180 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2021 | 19 | 0.180 |
Why?
| | Furin | 1 | 2021 | 14 | 0.180 |
Why?
| | Asia | 1 | 2021 | 67 | 0.180 |
Why?
| | Male | 21 | 2025 | 70910 | 0.180 |
Why?
| | Africa | 1 | 2021 | 113 | 0.180 |
Why?
| | Biomedical Research | 2 | 2018 | 692 | 0.180 |
Why?
| | Molecular Docking Simulation | 1 | 2021 | 116 | 0.170 |
Why?
| | Epidemiological Monitoring | 1 | 2021 | 70 | 0.170 |
Why?
| | Adenosine Monophosphate | 1 | 2021 | 77 | 0.170 |
Why?
| | Genome Size | 1 | 2020 | 11 | 0.170 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 150 | 0.170 |
Why?
| | Transcription, Genetic | 6 | 2023 | 1498 | 0.170 |
Why?
| | Alanine | 1 | 2021 | 165 | 0.170 |
Why?
| | Middle Aged | 14 | 2025 | 35049 | 0.170 |
Why?
| | Europe | 1 | 2021 | 410 | 0.170 |
Why?
| | Models, Molecular | 3 | 2016 | 1616 | 0.160 |
Why?
| | HEK293 Cells | 2 | 2021 | 747 | 0.160 |
Why?
| | Structure-Activity Relationship | 2 | 2016 | 573 | 0.160 |
Why?
| | Bacteriological Techniques | 1 | 2021 | 67 | 0.160 |
Why?
| | Water Pollution | 1 | 2020 | 9 | 0.160 |
Why?
| | Metagenome | 1 | 2021 | 148 | 0.160 |
Why?
| | Water Quality | 1 | 2020 | 35 | 0.160 |
Why?
| | Killer Cells, Natural | 2 | 2014 | 473 | 0.160 |
Why?
| | Antigens, Bacterial | 2 | 2014 | 125 | 0.160 |
Why?
| | Bone Neoplasms | 1 | 2022 | 249 | 0.150 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2020 | 81 | 0.150 |
Why?
| | Membrane Lipids | 1 | 2020 | 82 | 0.150 |
Why?
| | Immune Evasion | 1 | 2020 | 64 | 0.150 |
Why?
| | Adaptation, Physiological | 3 | 2023 | 567 | 0.150 |
Why?
| | Bone and Bones | 1 | 2022 | 314 | 0.150 |
Why?
| | Apolipoproteins E | 1 | 2019 | 91 | 0.150 |
Why?
| | Pneumonia | 2 | 2023 | 643 | 0.150 |
Why?
| | Aged | 11 | 2025 | 25117 | 0.150 |
Why?
| | Protein Conformation | 2 | 2016 | 941 | 0.140 |
Why?
| | Phospholipids | 1 | 2020 | 211 | 0.140 |
Why?
| | Adult | 14 | 2025 | 39715 | 0.140 |
Why?
| | Female | 17 | 2025 | 76624 | 0.140 |
Why?
| | Binding Sites | 1 | 2021 | 1317 | 0.140 |
Why?
| | Databases, Factual | 2 | 2021 | 1458 | 0.140 |
Why?
| | Host-Pathogen Interactions | 3 | 2016 | 369 | 0.140 |
Why?
| | Training Support | 1 | 2018 | 36 | 0.140 |
Why?
| | Mycolic Acids | 1 | 2017 | 7 | 0.140 |
Why?
| | Fomites | 1 | 2017 | 7 | 0.140 |
Why?
| | Base Composition | 1 | 2017 | 81 | 0.130 |
Why?
| | Neurofilament Proteins | 2 | 2025 | 62 | 0.130 |
Why?
| | Oregon | 1 | 2017 | 80 | 0.130 |
Why?
| | Virus Diseases | 1 | 2020 | 218 | 0.130 |
Why?
| | Longitudinal Studies | 3 | 2025 | 2980 | 0.130 |
Why?
| | Biological Specimen Banks | 1 | 2018 | 98 | 0.130 |
Why?
| | Valsalva Maneuver | 1 | 2017 | 10 | 0.130 |
Why?
| | Disease | 1 | 2018 | 98 | 0.130 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1881 | 0.130 |
Why?
| | Water Supply | 1 | 2017 | 89 | 0.130 |
Why?
| | Surgical Equipment | 1 | 2016 | 10 | 0.130 |
Why?
| | Sensation Disorders | 1 | 2017 | 41 | 0.120 |
Why?
| | Brazil | 2 | 2014 | 177 | 0.120 |
Why?
| | DNA Gyrase | 1 | 2016 | 12 | 0.120 |
Why?
| | Family | 1 | 2021 | 682 | 0.120 |
Why?
| | Gait Disorders, Neurologic | 1 | 2017 | 46 | 0.120 |
Why?
| | Fluoroquinolones | 1 | 2016 | 43 | 0.120 |
Why?
| | Web Browser | 1 | 2015 | 13 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2018 | 269 | 0.120 |
Why?
| | Gene Ontology | 1 | 2015 | 51 | 0.120 |
Why?
| | Catalase | 1 | 2016 | 134 | 0.120 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2015 | 27 | 0.120 |
Why?
| | Language Disorders | 1 | 2015 | 30 | 0.120 |
Why?
| | Social Perception | 1 | 2017 | 105 | 0.120 |
Why?
| | Molecular Sequence Annotation | 1 | 2015 | 99 | 0.120 |
Why?
| | Career Choice | 1 | 2018 | 234 | 0.120 |
Why?
| | Rifampin | 1 | 2016 | 82 | 0.120 |
Why?
| | Mentors | 1 | 2018 | 214 | 0.120 |
Why?
| | Antiviral Agents | 1 | 2021 | 758 | 0.120 |
Why?
| | Mouth Mucosa | 1 | 2016 | 90 | 0.120 |
Why?
| | Isoniazid | 1 | 2016 | 65 | 0.120 |
Why?
| | Bacterial Toxins | 1 | 2016 | 104 | 0.120 |
Why?
| | Housing | 1 | 2016 | 147 | 0.120 |
Why?
| | Octamer Transcription Factors | 1 | 2015 | 3 | 0.120 |
Why?
| | Nuclear Matrix-Associated Proteins | 1 | 2015 | 7 | 0.120 |
Why?
| | Genes, Viral | 1 | 2015 | 92 | 0.120 |
Why?
| | Virus Activation | 1 | 2016 | 86 | 0.110 |
Why?
| | Cohort Studies | 6 | 2025 | 5858 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 204 | 0.110 |
Why?
| | Tumor Escape | 1 | 2015 | 47 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 548 | 0.110 |
Why?
| | Data Mining | 1 | 2016 | 117 | 0.110 |
Why?
| | Herpesviridae | 1 | 2014 | 22 | 0.110 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2015 | 100 | 0.110 |
Why?
| | Viral Core Proteins | 1 | 2014 | 22 | 0.110 |
Why?
| | Education, Medical | 1 | 2018 | 275 | 0.110 |
Why?
| | Adaptive Immunity | 1 | 2016 | 170 | 0.110 |
Why?
| | Neuroimaging | 1 | 2017 | 279 | 0.110 |
Why?
| | Retroviridae | 1 | 2014 | 103 | 0.110 |
Why?
| | Tuberculosis Vaccines | 1 | 2014 | 5 | 0.110 |
Why?
| | Genetic Linkage | 2 | 2006 | 288 | 0.110 |
Why?
| | Colorado | 5 | 2024 | 4638 | 0.100 |
Why?
| | Biofilms | 1 | 2016 | 276 | 0.100 |
Why?
| | Aged, 80 and over | 6 | 2025 | 8020 | 0.100 |
Why?
| | RNA, Untranslated | 1 | 2015 | 124 | 0.100 |
Why?
| | Postural Balance | 1 | 2017 | 241 | 0.100 |
Why?
| | Operon | 2 | 2003 | 69 | 0.100 |
Why?
| | Language | 1 | 2017 | 317 | 0.100 |
Why?
| | Biomarkers | 3 | 2025 | 4207 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3776 | 0.100 |
Why?
| | Survival Analysis | 1 | 2017 | 1328 | 0.100 |
Why?
| | Extracellular Vesicles | 1 | 2016 | 160 | 0.100 |
Why?
| | Brain Concussion | 1 | 2021 | 592 | 0.100 |
Why?
| | Heterozygote | 1 | 2014 | 308 | 0.100 |
Why?
| | B-Lymphocytes | 2 | 2016 | 875 | 0.100 |
Why?
| | Conserved Sequence | 2 | 2003 | 239 | 0.100 |
Why?
| | Lymphoma | 1 | 2014 | 228 | 0.100 |
Why?
| | Galectins | 1 | 2013 | 27 | 0.100 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5700 | 0.100 |
Why?
| | Hepacivirus | 1 | 2014 | 242 | 0.090 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2020 | 669 | 0.090 |
Why?
| | Phenotype | 3 | 2016 | 3184 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1501 | 0.090 |
Why?
| | Virulence Factors | 1 | 2014 | 171 | 0.090 |
Why?
| | Genetic Association Studies | 1 | 2014 | 375 | 0.090 |
Why?
| | Epidemics | 1 | 2013 | 95 | 0.090 |
Why?
| | Motor Activity | 1 | 2017 | 717 | 0.090 |
Why?
| | Amyloid beta-Peptides | 2 | 2025 | 234 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2013 | 148 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2103 | 0.090 |
Why?
| | Sequence Analysis, RNA | 1 | 2014 | 445 | 0.090 |
Why?
| | RNA-Binding Proteins | 1 | 2015 | 454 | 0.080 |
Why?
| | Young Adult | 5 | 2025 | 13878 | 0.080 |
Why?
| | DNA, Viral | 1 | 2012 | 364 | 0.080 |
Why?
| | Nerve Tissue Proteins | 1 | 2014 | 607 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5270 | 0.080 |
Why?
| | Base Sequence | 1 | 2013 | 2176 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2021 | 3604 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2016 | 1116 | 0.080 |
Why?
| | Activities of Daily Living | 2 | 2023 | 429 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2023 | 5967 | 0.080 |
Why?
| | MicroRNAs | 1 | 2016 | 696 | 0.070 |
Why?
| | Time Factors | 2 | 2021 | 7006 | 0.070 |
Why?
| | Species Specificity | 2 | 2020 | 574 | 0.070 |
Why?
| | Bayes Theorem | 2 | 2021 | 424 | 0.070 |
Why?
| | Signal Transduction | 2 | 2016 | 5163 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2015 | 2927 | 0.070 |
Why?
| | Public Health | 1 | 2012 | 561 | 0.070 |
Why?
| | Cell Wall | 2 | 2006 | 61 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2608 | 0.060 |
Why?
| | Mice | 5 | 2023 | 18172 | 0.060 |
Why?
| | Treatment Failure | 2 | 2021 | 357 | 0.060 |
Why?
| | Uganda | 2 | 2016 | 88 | 0.060 |
Why?
| | Solubility | 1 | 2006 | 239 | 0.060 |
Why?
| | Cloning, Molecular | 1 | 2006 | 532 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2023 | 4483 | 0.060 |
Why?
| | Diffusion Tensor Imaging | 1 | 2025 | 75 | 0.060 |
Why?
| | Crystallography, X-Ray | 1 | 2006 | 487 | 0.050 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2025 | 112 | 0.050 |
Why?
| | Atrophy | 1 | 2025 | 196 | 0.050 |
Why?
| | Protein Kinases | 2 | 2016 | 309 | 0.050 |
Why?
| | Arizona | 1 | 2024 | 81 | 0.050 |
Why?
| | C9orf72 Protein | 2 | 2014 | 13 | 0.050 |
Why?
| | Glutamate-Ammonia Ligase | 1 | 2003 | 7 | 0.050 |
Why?
| | Galactans | 1 | 2003 | 5 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 759 | 0.050 |
Why?
| | Iron | 2 | 2022 | 338 | 0.050 |
Why?
| | Mexico | 1 | 2024 | 230 | 0.050 |
Why?
| | Dust | 1 | 2023 | 99 | 0.050 |
Why?
| | Genome | 1 | 2006 | 308 | 0.050 |
Why?
| | Risk Factors | 3 | 2025 | 10593 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2014 | 221 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3362 | 0.050 |
Why?
| | Animals | 6 | 2023 | 37697 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2024 | 187 | 0.050 |
Why?
| | Proteome | 2 | 2006 | 491 | 0.050 |
Why?
| | Mycobacterium avium Complex | 1 | 2023 | 88 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 743 | 0.050 |
Why?
| | Oxides | 1 | 2022 | 51 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2025 | 16626 | 0.040 |
Why?
| | Clarithromycin | 1 | 2021 | 24 | 0.040 |
Why?
| | HIV Infections | 1 | 2016 | 3003 | 0.040 |
Why?
| | Armadillos | 1 | 2021 | 2 | 0.040 |
Why?
| | Mycobacterium leprae | 1 | 2021 | 10 | 0.040 |
Why?
| | Macrolides | 1 | 2021 | 69 | 0.040 |
Why?
| | Clone Cells | 1 | 2021 | 270 | 0.040 |
Why?
| | Cell Membrane | 2 | 2020 | 706 | 0.040 |
Why?
| | Benchmarking | 1 | 2022 | 181 | 0.040 |
Why?
| | Smokers | 1 | 2021 | 146 | 0.040 |
Why?
| | Adolescent | 4 | 2025 | 22326 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2023 | 1053 | 0.040 |
Why?
| | Bone Marrow | 1 | 2022 | 299 | 0.040 |
Why?
| | Bioreactors | 1 | 2021 | 49 | 0.040 |
Why?
| | Spine | 1 | 2022 | 179 | 0.040 |
Why?
| | Macrophages | 2 | 2020 | 1496 | 0.040 |
Why?
| | Microbial Viability | 1 | 2021 | 91 | 0.040 |
Why?
| | Chromatography, Thin Layer | 1 | 2020 | 25 | 0.040 |
Why?
| | Water | 1 | 2023 | 469 | 0.040 |
Why?
| | THP-1 Cells | 1 | 2020 | 19 | 0.040 |
Why?
| | Cathelicidins | 1 | 2020 | 41 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 49 | 0.040 |
Why?
| | Genetics, Population | 1 | 2021 | 212 | 0.040 |
Why?
| | Apolipoprotein E4 | 1 | 2019 | 38 | 0.040 |
Why?
| | Mice, Nude | 1 | 2021 | 701 | 0.040 |
Why?
| | Cell Line | 2 | 2015 | 2878 | 0.040 |
Why?
| | Global Health | 1 | 2021 | 387 | 0.040 |
Why?
| | Age Factors | 1 | 2025 | 3316 | 0.030 |
Why?
| | RNA, Messenger | 2 | 2016 | 2828 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 717 | 0.030 |
Why?
| | Behavior, Animal | 1 | 2021 | 515 | 0.030 |
Why?
| | Child | 3 | 2025 | 22562 | 0.030 |
Why?
| | Disease Progression | 1 | 2025 | 2831 | 0.030 |
Why?
| | Membrane Proteins | 2 | 2014 | 1160 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2012 | 2916 | 0.030 |
Why?
| | Macrophages, Alveolar | 1 | 2020 | 372 | 0.030 |
Why?
| | Gambia | 1 | 2016 | 8 | 0.030 |
Why?
| | Hospitals | 1 | 2021 | 690 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2023 | 952 | 0.030 |
Why?
| | Regulon | 1 | 2016 | 36 | 0.030 |
Why?
| | Nitrogen Oxides | 1 | 2016 | 54 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2014 | 3546 | 0.030 |
Why?
| | Granuloma | 1 | 2016 | 97 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2017 | 432 | 0.030 |
Why?
| | India | 1 | 2016 | 214 | 0.030 |
Why?
| | Palatine Tonsil | 1 | 2016 | 55 | 0.030 |
Why?
| | Body Temperature Regulation | 1 | 2016 | 102 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2016 | 156 | 0.030 |
Why?
| | Escherichia coli | 1 | 2020 | 832 | 0.030 |
Why?
| | Replication Origin | 1 | 2015 | 21 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 189 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1249 | 0.030 |
Why?
| | Prevalence | 1 | 2022 | 2817 | 0.030 |
Why?
| | Specimen Handling | 1 | 2016 | 181 | 0.030 |
Why?
| | Latent Tuberculosis | 1 | 2015 | 70 | 0.030 |
Why?
| | Ataxins | 1 | 2014 | 4 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2014 | 37 | 0.030 |
Why?
| | Survival of Motor Neuron 2 Protein | 1 | 2014 | 5 | 0.030 |
Why?
| | Virus Integration | 1 | 2014 | 70 | 0.030 |
Why?
| | Survival of Motor Neuron 1 Protein | 1 | 2014 | 13 | 0.030 |
Why?
| | Multilocus Sequence Typing | 1 | 2014 | 17 | 0.030 |
Why?
| | Motor Neuron Disease | 1 | 2014 | 21 | 0.030 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 87 | 0.030 |
Why?
| | Saliva | 1 | 2016 | 246 | 0.030 |
Why?
| | Extracellular Space | 1 | 2014 | 129 | 0.030 |
Why?
| | Guinea Pigs | 1 | 2014 | 162 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1508 | 0.030 |
Why?
| | Cell Count | 1 | 2014 | 320 | 0.030 |
Why?
| | ROC Curve | 1 | 2015 | 600 | 0.030 |
Why?
| | Accidental Falls | 1 | 2017 | 228 | 0.030 |
Why?
| | Burkitt Lymphoma | 1 | 2014 | 63 | 0.030 |
Why?
| | Autopsy | 1 | 2013 | 98 | 0.020 |
Why?
| | Patient Outcome Assessment | 1 | 2014 | 132 | 0.020 |
Why?
| | Muromegalovirus | 1 | 2013 | 23 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1051 | 0.020 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2013 | 30 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2014 | 326 | 0.020 |
Why?
| | United Kingdom | 1 | 2014 | 325 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1319 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2017 | 582 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2016 | 396 | 0.020 |
Why?
| | Receptors, Virus | 1 | 2013 | 95 | 0.020 |
Why?
| | Interferons | 1 | 2014 | 195 | 0.020 |
Why?
| | Interleukin-15 | 1 | 2013 | 99 | 0.020 |
Why?
| | Interleukin-12 | 1 | 2013 | 123 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 385 | 0.020 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 198 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 315 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 388 | 0.020 |
Why?
| | Hepatitis C | 1 | 2014 | 253 | 0.020 |
Why?
| | Drug Discovery | 1 | 2012 | 148 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7862 | 0.020 |
Why?
| | Genetic Testing | 1 | 2013 | 468 | 0.020 |
Why?
| | NF-kappa B | 1 | 2014 | 684 | 0.020 |
Why?
| | Viral Proteins | 1 | 2012 | 370 | 0.020 |
Why?
| | Hypoxia | 1 | 2016 | 1166 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1220 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2010 | 2150 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2010 | 1727 | 0.020 |
Why?
| | Phosphorylation | 1 | 2010 | 1758 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2013 | 3081 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2013 | 4167 | 0.010 |
Why?
| | Vaccination | 1 | 2014 | 1479 | 0.010 |
Why?
| | Biological Transport | 1 | 2006 | 410 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5994 | 0.010 |
Why?
| | DNA Repair | 1 | 2006 | 246 | 0.010 |
Why?
| | Up-Regulation | 1 | 2006 | 857 | 0.010 |
Why?
| | Lipid Metabolism | 1 | 2006 | 522 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 505 | 0.010 |
Why?
|
|
Strong's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|